RECIPIENT CONSENT 
PAGE 5 
it is possible that despite all of our efforts, other unforeseen, perhaps serious and life- 
threatening, problems may occur. 
The potential benefit to you would be improved treatment of HIV infection using 
a new therapeutic approach that you tolerate well. The potential benefit to others 
would be the development of further knowledge about the safety, side effects, and 
survival of gene marked cells when given to HIV-infected patients, and possibly the 
development of a new strategy for treating HIV infection. 
Therapy for HIV infection is an area of intense research. Zidovudine has been 
shown to be of benefit and is currently licensed for treating HIV infection in those with 
less than 500 CD4 cells. Dideoxyinosine (ddl) has recently been approved by the 
FDA for the treatment of patients who either cannot tolerate or who are no longer 
responding to zidovudine. A third drug, dideoxycytidine (ddC), is also licensed for the 
treatment of HIV infection in combination with zidovudine. In addition to these 
available antiviral drugs, preventing PCP with oral trimethoprim-sulfamethoxazole or 
aerosolized pentamidine has also been shown to prolong the lives of patients at risk 
for PCP. Other potentially promising therapies for HIV infection are under study and 
may be available to you at this or another institution. 
In certain circumstances, some patients may need to terminate their 
participation in the study. You are free to withdraw at any time and for any reason 
without prejudice from the investigators. Serious side effects may cause you to be 
removed from the study at the discretion of the principal investigator. Other reasons for 
terminating your participation on the protocol include: the development of a life- 
threatening malignancy; noncompliance with clinic visits and other terms of the 
protocol; termination of the study by the principal investigator or the FDA; judgment of 
the principal investigator that it is in your best medical interest to leave the study. 
There is no cost to you for the procedures associated with this study, but if you 
require medical care at other institutions or from other physicians during the course of 
this study, you or your insurance will be charged for this care. Antiviral therapies such 
as AZT, ddl, and ddC, and PCP prophylaxis will not be provided by the NIH and must 
be prescribed when indicated by your personal physician. Once your participation in 
this protocol is completed, you will not be eligible for continuing care at NIH, but your 
doctors at NIH will be glad to provide telephone consultation to your home doctor at 
any time. If physical injury results from your participation in this study, immediate 
necessary medical care will be provided, but there is no provision for free medical care 
or for monetary compensation for such injury. Letters and results of tests performed at 
the NIH will be sent to your personal physician, and you are encouraged to remain in 
close contact with your doctor. You must receive routine medical care from your own 
physician, and you may not rely on the NIH for general medical care. 
[320] 
Recombinant DNA Research, Volume 16 
